nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—HTR2A—myenteric nerve plexus—colon cancer	0.0224	0.236	CbGeAlD
Zuclopenthixol—HTR2A—vein—colon cancer	0.0144	0.152	CbGeAlD
Zuclopenthixol—DRD5—lymphoid tissue—colon cancer	0.00576	0.0609	CbGeAlD
Zuclopenthixol—HTR2A—endothelium—colon cancer	0.00496	0.0524	CbGeAlD
Zuclopenthixol—HTR2A—blood vessel—colon cancer	0.00457	0.0483	CbGeAlD
Zuclopenthixol—ADRA1A—epithelium—colon cancer	0.00344	0.0364	CbGeAlD
Zuclopenthixol—ADRA1A—renal system—colon cancer	0.00319	0.0338	CbGeAlD
Zuclopenthixol—Flupentixol—ABCB1—colon cancer	0.00309	0.211	CrCbGaD
Zuclopenthixol—Mental disorder—Vincristine—colon cancer	0.00294	0.0033	CcSEcCtD
Zuclopenthixol—Urine output increased—Methotrexate—colon cancer	0.00293	0.00329	CcSEcCtD
Zuclopenthixol—Arrhythmia—Irinotecan—colon cancer	0.00292	0.00328	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Capecitabine—colon cancer	0.00292	0.00328	CcSEcCtD
Zuclopenthixol—Gynaecomastia—Methotrexate—colon cancer	0.0029	0.00326	CcSEcCtD
Zuclopenthixol—Breast disorder—Capecitabine—colon cancer	0.00286	0.00321	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Capecitabine—colon cancer	0.00283	0.00317	CcSEcCtD
Zuclopenthixol—Flatulence—Irinotecan—colon cancer	0.0028	0.00315	CcSEcCtD
Zuclopenthixol—Arrhythmia—Fluorouracil—colon cancer	0.00279	0.00314	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00279	0.00313	CcSEcCtD
Zuclopenthixol—HTR2A—embryo—colon cancer	0.00273	0.0288	CbGeAlD
Zuclopenthixol—Erythema—Fluorouracil—colon cancer	0.00272	0.00306	CcSEcCtD
Zuclopenthixol—Agitation—Vincristine—colon cancer	0.00268	0.00301	CcSEcCtD
Zuclopenthixol—Polyuria—Methotrexate—colon cancer	0.00268	0.00301	CcSEcCtD
Zuclopenthixol—HRH1—epithelium—colon cancer	0.00266	0.0282	CbGeAlD
Zuclopenthixol—Sweating increased—Capecitabine—colon cancer	0.00266	0.00299	CcSEcCtD
Zuclopenthixol—ADRA1A—lymphoid tissue—colon cancer	0.00265	0.028	CbGeAlD
Zuclopenthixol—Ill-defined disorder—Irinotecan—colon cancer	0.00264	0.00296	CcSEcCtD
Zuclopenthixol—Vertigo—Vincristine—colon cancer	0.00262	0.00294	CcSEcCtD
Zuclopenthixol—Leukopenia—Vincristine—colon cancer	0.00261	0.00293	CcSEcCtD
Zuclopenthixol—Pancytopenia—Capecitabine—colon cancer	0.00259	0.00291	CcSEcCtD
Zuclopenthixol—HRH1—smooth muscle tissue—colon cancer	0.00257	0.0271	CbGeAlD
Zuclopenthixol—Vision blurred—Fluorouracil—colon cancer	0.00257	0.00288	CcSEcCtD
Zuclopenthixol—Malaise—Irinotecan—colon cancer	0.00256	0.00288	CcSEcCtD
Zuclopenthixol—Vertigo—Irinotecan—colon cancer	0.00255	0.00287	CcSEcCtD
Zuclopenthixol—Dysuria—Capecitabine—colon cancer	0.00255	0.00287	CcSEcCtD
Zuclopenthixol—Neutropenia—Capecitabine—colon cancer	0.00255	0.00287	CcSEcCtD
Zuclopenthixol—Syncope—Irinotecan—colon cancer	0.00255	0.00286	CcSEcCtD
Zuclopenthixol—Leukopenia—Irinotecan—colon cancer	0.00255	0.00286	CcSEcCtD
Zuclopenthixol—Convulsion—Vincristine—colon cancer	0.00253	0.00284	CcSEcCtD
Zuclopenthixol—Hypertension—Vincristine—colon cancer	0.00252	0.00283	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Irinotecan—colon cancer	0.0025	0.00281	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Capecitabine—colon cancer	0.00249	0.0028	CcSEcCtD
Zuclopenthixol—Myalgia—Vincristine—colon cancer	0.00249	0.00279	CcSEcCtD
Zuclopenthixol—Weight increased—Capecitabine—colon cancer	0.00249	0.00279	CcSEcCtD
Zuclopenthixol—Weight decreased—Capecitabine—colon cancer	0.00247	0.00277	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Capecitabine—colon cancer	0.00246	0.00277	CcSEcCtD
Zuclopenthixol—Hypertension—Irinotecan—colon cancer	0.00245	0.00276	CcSEcCtD
Zuclopenthixol—Leukopenia—Fluorouracil—colon cancer	0.00244	0.00274	CcSEcCtD
Zuclopenthixol—Discomfort—Irinotecan—colon cancer	0.00239	0.00269	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Vincristine—colon cancer	0.00238	0.00268	CcSEcCtD
Zuclopenthixol—Jaundice—Capecitabine—colon cancer	0.00237	0.00266	CcSEcCtD
Zuclopenthixol—Convulsion—Fluorouracil—colon cancer	0.00236	0.00265	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Vincristine—colon cancer	0.00234	0.00262	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Vincristine—colon cancer	0.00233	0.00262	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Irinotecan—colon cancer	0.00232	0.00261	CcSEcCtD
Zuclopenthixol—Myalgia—Fluorouracil—colon cancer	0.00232	0.0026	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Vincristine—colon cancer	0.0023	0.00259	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Capecitabine—colon cancer	0.0023	0.00259	CcSEcCtD
Zuclopenthixol—Discomfort—Fluorouracil—colon cancer	0.00229	0.00257	CcSEcCtD
Zuclopenthixol—Shock—Irinotecan—colon cancer	0.00228	0.00256	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Irinotecan—colon cancer	0.00228	0.00255	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Capecitabine—colon cancer	0.00227	0.00255	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Irinotecan—colon cancer	0.00227	0.00255	CcSEcCtD
Zuclopenthixol—Anorexia—Vincristine—colon cancer	0.00227	0.00255	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Irinotecan—colon cancer	0.00224	0.00252	CcSEcCtD
Zuclopenthixol—Hypotension—Vincristine—colon cancer	0.00223	0.0025	CcSEcCtD
Zuclopenthixol—HTR2A—epithelium—colon cancer	0.00223	0.0235	CbGeAlD
Zuclopenthixol—Anaphylactic shock—Fluorouracil—colon cancer	0.00222	0.0025	CcSEcCtD
Zuclopenthixol—Anorexia—Irinotecan—colon cancer	0.00221	0.00248	CcSEcCtD
Zuclopenthixol—Ataxia—Methotrexate—colon cancer	0.00221	0.00248	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Fluorouracil—colon cancer	0.00218	0.00245	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Fluorouracil—colon cancer	0.00218	0.00244	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Methotrexate—colon cancer	0.00217	0.00244	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Vincristine—colon cancer	0.00217	0.00244	CcSEcCtD
Zuclopenthixol—Tachycardia—Fluorouracil—colon cancer	0.00217	0.00244	CcSEcCtD
Zuclopenthixol—Hypotension—Irinotecan—colon cancer	0.00217	0.00243	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Capecitabine—colon cancer	0.00216	0.00242	CcSEcCtD
Zuclopenthixol—Insomnia—Vincristine—colon cancer	0.00216	0.00242	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Capecitabine—colon cancer	0.00215	0.00242	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Capecitabine—colon cancer	0.00215	0.00241	CcSEcCtD
Zuclopenthixol—HTR2A—smooth muscle tissue—colon cancer	0.00214	0.0227	CbGeAlD
Zuclopenthixol—Urethral disorder—Capecitabine—colon cancer	0.00214	0.00241	CcSEcCtD
Zuclopenthixol—Paraesthesia—Vincristine—colon cancer	0.00214	0.0024	CcSEcCtD
Zuclopenthixol—Breast disorder—Methotrexate—colon cancer	0.00213	0.00239	CcSEcCtD
Zuclopenthixol—Anorexia—Fluorouracil—colon cancer	0.00212	0.00238	CcSEcCtD
Zuclopenthixol—Visual impairment—Capecitabine—colon cancer	0.00211	0.00237	CcSEcCtD
Zuclopenthixol—Insomnia—Irinotecan—colon cancer	0.0021	0.00236	CcSEcCtD
Zuclopenthixol—Paraesthesia—Irinotecan—colon cancer	0.00208	0.00234	CcSEcCtD
Zuclopenthixol—Hypotension—Fluorouracil—colon cancer	0.00208	0.00233	CcSEcCtD
Zuclopenthixol—Domperidone—ABCB1—colon cancer	0.00208	0.142	CrCbGaD
Zuclopenthixol—Decreased appetite—Vincristine—colon cancer	0.00207	0.00233	CcSEcCtD
Zuclopenthixol—Dyspnoea—Irinotecan—colon cancer	0.00207	0.00232	CcSEcCtD
Zuclopenthixol—HTR2A—renal system—colon cancer	0.00206	0.0218	CbGeAlD
Zuclopenthixol—Somnolence—Irinotecan—colon cancer	0.00206	0.00232	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Vincristine—colon cancer	0.00206	0.00231	CcSEcCtD
Zuclopenthixol—Fatigue—Vincristine—colon cancer	0.00205	0.00231	CcSEcCtD
Zuclopenthixol—Eye disorder—Capecitabine—colon cancer	0.00204	0.00229	CcSEcCtD
Zuclopenthixol—Dyspepsia—Irinotecan—colon cancer	0.00204	0.00229	CcSEcCtD
Zuclopenthixol—Tinnitus—Capecitabine—colon cancer	0.00204	0.00229	CcSEcCtD
Zuclopenthixol—Constipation—Vincristine—colon cancer	0.00204	0.00229	CcSEcCtD
Zuclopenthixol—Pain—Vincristine—colon cancer	0.00204	0.00229	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Capecitabine—colon cancer	0.00203	0.00228	CcSEcCtD
Zuclopenthixol—HRH1—digestive system—colon cancer	0.00203	0.0214	CbGeAlD
Zuclopenthixol—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00203	0.00227	CcSEcCtD
Zuclopenthixol—Decreased appetite—Irinotecan—colon cancer	0.00202	0.00226	CcSEcCtD
Zuclopenthixol—Eosinophilia—Methotrexate—colon cancer	0.00201	0.00226	CcSEcCtD
Zuclopenthixol—Insomnia—Fluorouracil—colon cancer	0.00201	0.00226	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Irinotecan—colon cancer	0.002	0.00225	CcSEcCtD
Zuclopenthixol—Fatigue—Irinotecan—colon cancer	0.002	0.00225	CcSEcCtD
Zuclopenthixol—Paraesthesia—Fluorouracil—colon cancer	0.002	0.00224	CcSEcCtD
Zuclopenthixol—Constipation—Irinotecan—colon cancer	0.00198	0.00223	CcSEcCtD
Zuclopenthixol—Pain—Irinotecan—colon cancer	0.00198	0.00223	CcSEcCtD
Zuclopenthixol—Angiopathy—Capecitabine—colon cancer	0.00198	0.00223	CcSEcCtD
Zuclopenthixol—Dyspnoea—Fluorouracil—colon cancer	0.00198	0.00222	CcSEcCtD
Zuclopenthixol—Somnolence—Fluorouracil—colon cancer	0.00198	0.00222	CcSEcCtD
Zuclopenthixol—Immune system disorder—Capecitabine—colon cancer	0.00197	0.00222	CcSEcCtD
Zuclopenthixol—Dyspepsia—Fluorouracil—colon cancer	0.00196	0.0022	CcSEcCtD
Zuclopenthixol—Arrhythmia—Capecitabine—colon cancer	0.00195	0.00219	CcSEcCtD
Zuclopenthixol—ADRA1A—liver—colon cancer	0.00195	0.0206	CbGeAlD
Zuclopenthixol—Gastrointestinal pain—Vincristine—colon cancer	0.00195	0.00219	CcSEcCtD
Zuclopenthixol—Decreased appetite—Fluorouracil—colon cancer	0.00193	0.00217	CcSEcCtD
Zuclopenthixol—Pancytopenia—Methotrexate—colon cancer	0.00193	0.00217	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00192	0.00215	CcSEcCtD
Zuclopenthixol—Mental disorder—Capecitabine—colon cancer	0.00192	0.00215	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Irinotecan—colon cancer	0.00191	0.00215	CcSEcCtD
Zuclopenthixol—Malnutrition—Capecitabine—colon cancer	0.0019	0.00214	CcSEcCtD
Zuclopenthixol—Erythema—Capecitabine—colon cancer	0.0019	0.00214	CcSEcCtD
Zuclopenthixol—Neutropenia—Methotrexate—colon cancer	0.0019	0.00213	CcSEcCtD
Zuclopenthixol—Dysuria—Methotrexate—colon cancer	0.0019	0.00213	CcSEcCtD
Zuclopenthixol—Pain—Fluorouracil—colon cancer	0.0019	0.00213	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Irinotecan—colon cancer	0.0019	0.00213	CcSEcCtD
Zuclopenthixol—Abdominal pain—Vincristine—colon cancer	0.00188	0.00211	CcSEcCtD
Zuclopenthixol—Body temperature increased—Vincristine—colon cancer	0.00188	0.00211	CcSEcCtD
Zuclopenthixol—CYP2D6—renal system—colon cancer	0.00188	0.0199	CbGeAlD
Zuclopenthixol—Flatulence—Capecitabine—colon cancer	0.00188	0.00211	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Methotrexate—colon cancer	0.00187	0.0021	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Methotrexate—colon cancer	0.00186	0.00208	CcSEcCtD
Zuclopenthixol—Abdominal pain—Irinotecan—colon cancer	0.00183	0.00206	CcSEcCtD
Zuclopenthixol—Body temperature increased—Irinotecan—colon cancer	0.00183	0.00206	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Fluorouracil—colon cancer	0.00183	0.00206	CcSEcCtD
Zuclopenthixol—Drowsiness—Methotrexate—colon cancer	0.00181	0.00204	CcSEcCtD
Zuclopenthixol—Vision blurred—Capecitabine—colon cancer	0.00179	0.00201	CcSEcCtD
Zuclopenthixol—HRH1—vagina—colon cancer	0.00179	0.0189	CbGeAlD
Zuclopenthixol—Tremor—Capecitabine—colon cancer	0.00178	0.002	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Capecitabine—colon cancer	0.00177	0.00198	CcSEcCtD
Zuclopenthixol—ADRA2A—vagina—colon cancer	0.00176	0.0186	CbGeAlD
Zuclopenthixol—Body temperature increased—Fluorouracil—colon cancer	0.00176	0.00197	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Vincristine—colon cancer	0.00176	0.00197	CcSEcCtD
Zuclopenthixol—Sweating—Methotrexate—colon cancer	0.00174	0.00195	CcSEcCtD
Zuclopenthixol—Nefazodone—ABCB1—colon cancer	0.00172	0.118	CrCbGaD
Zuclopenthixol—Malaise—Capecitabine—colon cancer	0.00172	0.00193	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Methotrexate—colon cancer	0.00171	0.00192	CcSEcCtD
Zuclopenthixol—Vertigo—Capecitabine—colon cancer	0.00171	0.00192	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Irinotecan—colon cancer	0.00171	0.00192	CcSEcCtD
Zuclopenthixol—Asthenia—Vincristine—colon cancer	0.00171	0.00192	CcSEcCtD
Zuclopenthixol—Syncope—Capecitabine—colon cancer	0.00171	0.00192	CcSEcCtD
Zuclopenthixol—Leukopenia—Capecitabine—colon cancer	0.0017	0.00191	CcSEcCtD
Zuclopenthixol—HTR2A—digestive system—colon cancer	0.00169	0.0179	CbGeAlD
Zuclopenthixol—Agranulocytosis—Methotrexate—colon cancer	0.00169	0.0019	CcSEcCtD
Zuclopenthixol—Palpitations—Capecitabine—colon cancer	0.00168	0.00189	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Capecitabine—colon cancer	0.00167	0.00188	CcSEcCtD
Zuclopenthixol—Asthenia—Irinotecan—colon cancer	0.00167	0.00187	CcSEcCtD
Zuclopenthixol—Hypertension—Capecitabine—colon cancer	0.00164	0.00184	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Fluorouracil—colon cancer	0.00164	0.00184	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vincristine—colon cancer	0.00163	0.00183	CcSEcCtD
Zuclopenthixol—Myalgia—Capecitabine—colon cancer	0.00162	0.00182	CcSEcCtD
Zuclopenthixol—Anxiety—Capecitabine—colon cancer	0.00161	0.00181	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00161	0.00181	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Methotrexate—colon cancer	0.00161	0.0018	CcSEcCtD
Zuclopenthixol—Discomfort—Capecitabine—colon cancer	0.0016	0.0018	CcSEcCtD
Zuclopenthixol—Trazodone—ABCB1—colon cancer	0.0016	0.109	CrCbGaD
Zuclopenthixol—Urethral disorder—Methotrexate—colon cancer	0.0016	0.00179	CcSEcCtD
Zuclopenthixol—Diarrhoea—Irinotecan—colon cancer	0.00159	0.00178	CcSEcCtD
Zuclopenthixol—Dry mouth—Capecitabine—colon cancer	0.00158	0.00178	CcSEcCtD
Zuclopenthixol—Dizziness—Vincristine—colon cancer	0.00158	0.00177	CcSEcCtD
Zuclopenthixol—Pruritus—Fluorouracil—colon cancer	0.00157	0.00177	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—colon cancer	0.00157	0.00176	CcSEcCtD
Zuclopenthixol—CYP2D6—digestive system—colon cancer	0.00154	0.0163	CbGeAlD
Zuclopenthixol—Dizziness—Irinotecan—colon cancer	0.00153	0.00172	CcSEcCtD
Zuclopenthixol—Shock—Capecitabine—colon cancer	0.00153	0.00172	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Capecitabine—colon cancer	0.00152	0.00171	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—colon cancer	0.00152	0.00171	CcSEcCtD
Zuclopenthixol—Diarrhoea—Fluorouracil—colon cancer	0.00152	0.00171	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Capecitabine—colon cancer	0.00152	0.00171	CcSEcCtD
Zuclopenthixol—Tinnitus—Methotrexate—colon cancer	0.00152	0.0017	CcSEcCtD
Zuclopenthixol—Tachycardia—Capecitabine—colon cancer	0.00152	0.0017	CcSEcCtD
Zuclopenthixol—Vomiting—Vincristine—colon cancer	0.00152	0.0017	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—colon cancer	0.00151	0.0017	CcSEcCtD
Zuclopenthixol—Skin disorder—Capecitabine—colon cancer	0.00151	0.00169	CcSEcCtD
Zuclopenthixol—Rash—Vincristine—colon cancer	0.0015	0.00169	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Capecitabine—colon cancer	0.0015	0.00169	CcSEcCtD
Zuclopenthixol—Dermatitis—Vincristine—colon cancer	0.0015	0.00169	CcSEcCtD
Zuclopenthixol—HTR2A—vagina—colon cancer	0.00149	0.0158	CbGeAlD
Zuclopenthixol—Headache—Vincristine—colon cancer	0.00149	0.00168	CcSEcCtD
Zuclopenthixol—Anorexia—Capecitabine—colon cancer	0.00148	0.00166	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—colon cancer	0.00148	0.00166	CcSEcCtD
Zuclopenthixol—Vomiting—Irinotecan—colon cancer	0.00148	0.00166	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—colon cancer	0.00147	0.00165	CcSEcCtD
Zuclopenthixol—Dizziness—Fluorouracil—colon cancer	0.00147	0.00165	CcSEcCtD
Zuclopenthixol—Rash—Irinotecan—colon cancer	0.00146	0.00164	CcSEcCtD
Zuclopenthixol—Dermatitis—Irinotecan—colon cancer	0.00146	0.00164	CcSEcCtD
Zuclopenthixol—Headache—Irinotecan—colon cancer	0.00145	0.00163	CcSEcCtD
Zuclopenthixol—Hypotension—Capecitabine—colon cancer	0.00145	0.00163	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—colon cancer	0.00143	0.0016	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—colon cancer	0.00142	0.00159	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—colon cancer	0.00142	0.00159	CcSEcCtD
Zuclopenthixol—Nausea—Vincristine—colon cancer	0.00142	0.00159	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00142	0.00159	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—colon cancer	0.00141	0.00159	CcSEcCtD
Zuclopenthixol—Insomnia—Capecitabine—colon cancer	0.0014	0.00158	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—colon cancer	0.0014	0.00157	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—colon cancer	0.0014	0.00157	CcSEcCtD
Zuclopenthixol—Paraesthesia—Capecitabine—colon cancer	0.00139	0.00157	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—colon cancer	0.00139	0.00156	CcSEcCtD
Zuclopenthixol—Dyspnoea—Capecitabine—colon cancer	0.00138	0.00155	CcSEcCtD
Zuclopenthixol—Nausea—Irinotecan—colon cancer	0.00138	0.00155	CcSEcCtD
Zuclopenthixol—Dyspepsia—Capecitabine—colon cancer	0.00137	0.00153	CcSEcCtD
Zuclopenthixol—Decreased appetite—Capecitabine—colon cancer	0.00135	0.00152	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Capecitabine—colon cancer	0.00134	0.00151	CcSEcCtD
Zuclopenthixol—Fatigue—Capecitabine—colon cancer	0.00134	0.0015	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—colon cancer	0.00134	0.0015	CcSEcCtD
Zuclopenthixol—Pain—Capecitabine—colon cancer	0.00133	0.00149	CcSEcCtD
Zuclopenthixol—Constipation—Capecitabine—colon cancer	0.00133	0.00149	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—colon cancer	0.00132	0.00148	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—colon cancer	0.00131	0.00148	CcSEcCtD
Zuclopenthixol—Fluphenazine—ABCB1—colon cancer	0.00129	0.0882	CrCbGaD
Zuclopenthixol—Feeling abnormal—Capecitabine—colon cancer	0.00128	0.00144	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—colon cancer	0.00128	0.00143	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—colon cancer	0.00127	0.00143	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Capecitabine—colon cancer	0.00127	0.00143	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—colon cancer	0.00127	0.00142	CcSEcCtD
Zuclopenthixol—HTR2A—liver—colon cancer	0.00126	0.0133	CbGeAlD
Zuclopenthixol—Abdominal pain—Capecitabine—colon cancer	0.00123	0.00138	CcSEcCtD
Zuclopenthixol—Body temperature increased—Capecitabine—colon cancer	0.00123	0.00138	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—colon cancer	0.00123	0.00138	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—colon cancer	0.00121	0.00135	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.0012	0.00134	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—colon cancer	0.00119	0.00134	CcSEcCtD
Zuclopenthixol—Chlorprothixene—ABCB1—colon cancer	0.00118	0.0803	CrCbGaD
Zuclopenthixol—HRH1—lymph node—colon cancer	0.00116	0.0122	CbGeAlD
Zuclopenthixol—Anaphylactic shock—Methotrexate—colon cancer	0.00116	0.0013	CcSEcCtD
Zuclopenthixol—CYP2D6—liver—colon cancer	0.00115	0.0122	CbGeAlD
Zuclopenthixol—Hypersensitivity—Capecitabine—colon cancer	0.00114	0.00128	CcSEcCtD
Zuclopenthixol—ADRA2A—lymph node—colon cancer	0.00114	0.012	CbGeAlD
Zuclopenthixol—Nervous system disorder—Methotrexate—colon cancer	0.00113	0.00127	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—colon cancer	0.00113	0.00127	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—colon cancer	0.00112	0.00126	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—colon cancer	0.00112	0.00125	CcSEcCtD
Zuclopenthixol—Asthenia—Capecitabine—colon cancer	0.00111	0.00125	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—colon cancer	0.0011	0.00124	CcSEcCtD
Zuclopenthixol—Pruritus—Capecitabine—colon cancer	0.0011	0.00123	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—colon cancer	0.00108	0.00121	CcSEcCtD
Zuclopenthixol—Diarrhoea—Capecitabine—colon cancer	0.00106	0.00119	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00105	0.00118	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—colon cancer	0.00105	0.00117	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—colon cancer	0.00104	0.00117	CcSEcCtD
Zuclopenthixol—Trifluoperazine—ABCB1—colon cancer	0.00103	0.0705	CrCbGaD
Zuclopenthixol—Dyspnoea—Methotrexate—colon cancer	0.00103	0.00116	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—colon cancer	0.00103	0.00115	CcSEcCtD
Zuclopenthixol—Dizziness—Capecitabine—colon cancer	0.00103	0.00115	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—colon cancer	0.00102	0.00114	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—colon cancer	0.00101	0.00113	CcSEcCtD
Zuclopenthixol—Quetiapine—ABCB1—colon cancer	0.001	0.0684	CrCbGaD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—colon cancer	0.000998	0.00112	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—colon cancer	0.000997	0.00112	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—colon cancer	0.000989	0.00111	CcSEcCtD
Zuclopenthixol—Vomiting—Capecitabine—colon cancer	0.000988	0.00111	CcSEcCtD
Zuclopenthixol—Rash—Capecitabine—colon cancer	0.000979	0.0011	CcSEcCtD
Zuclopenthixol—Dermatitis—Capecitabine—colon cancer	0.000978	0.0011	CcSEcCtD
Zuclopenthixol—Headache—Capecitabine—colon cancer	0.000973	0.00109	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—colon cancer	0.000953	0.00107	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—colon cancer	0.000945	0.00106	CcSEcCtD
Zuclopenthixol—Nausea—Capecitabine—colon cancer	0.000923	0.00104	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—colon cancer	0.000914	0.00103	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—colon cancer	0.000914	0.00103	CcSEcCtD
Zuclopenthixol—Clozapine—ABCB1—colon cancer	0.000862	0.0588	CrCbGaD
Zuclopenthixol—Hypersensitivity—Methotrexate—colon cancer	0.000852	0.000956	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—colon cancer	0.00083	0.000931	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—colon cancer	0.000818	0.000918	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ABCB1—colon cancer	0.000811	0.0553	CrCbGaD
Zuclopenthixol—Diarrhoea—Methotrexate—colon cancer	0.000791	0.000888	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—colon cancer	0.000765	0.000858	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—colon cancer	0.000735	0.000825	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—colon cancer	0.000729	0.000818	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—colon cancer	0.000728	0.000818	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—colon cancer	0.000724	0.000813	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—colon cancer	0.000687	0.000771	CcSEcCtD
